OPHIHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 13 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores CollPlant Biotechnologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Quality (7): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on OPHI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Feb 2026 | D. Boral Capital | Downgrade | Hold | — |
| 28 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 20 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 21 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2024 | EF Hutton | Maintains | Buy | — |
| 5 Aug 2024 | EF Hutton | Initiates | Buy | — |
| 30 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OPHI appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Nov 2026, CollPlant Biotechnologies Ltd. returned −75.4% against +12.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 5% of US stocks
Cheaper than 38% of US stocks
Cheaper than 67% of US stocks
Higher than 7% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 97% of US stocks
Higher than 9% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CollPlant Biotechnologies Ltd. has a market value of $11.2M and an enterprise value of $6.8M.
Revenue in the twelve months to 31 Mar 2026: $389K. The latest quarter shrank 39.7% year on year.
Net income over the same four quarters: −$13.1M, a −3376.3% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$11.3M, after $25K of capital spending.
Trailing P/E: −3.9×; forward P/E: −11.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CollPlant Biotechnologies Ltd. employs 39 people — $10K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CollPlant Biotechnologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CollPlant will begin trading on Nasdaq under the ticker symbol OPHI. The company described the change as a step in its strategy to expand and focus operations around LightSolver’s all-optical Laser Processing Unit (LPU).
Why it matters — CLGN watchers may note the Nasdaq ticker change and the company’s stated operational focus on LightSolver’s LPU.
CollPlant Biotechnologies announced that its subsidiary, LightSolver Ltd., will unveil the first public demonstration of its all-optical computer at SC26.
Why it matters — The announcement concerns a subsidiary of CollPlant and may be relevant to CLGN watchers tracking company developments.
LightSolver received an approximately $1.8 million grant from Israel's Innovation Authority to advance its Laser Processing Unit hardware and expand the LPU Lab platform. The program follows the company's recent partnership with Boeing, peer-reviewed research with HLRS, and growth in its IP portfolio.
Why it matters — The item concerns LightSolver, not CollPlant, so it provides no direct company-specific development for CLGN watchers.
CollPlant Biotechnologies Ltd. said its Board of Directors approved a proposal to change the company’s name to OptiPhi Computing Ltd.
Why it matters — CLGN watchers may want to note the proposed change to the company’s name and its stated expansion to computing with light.
CollPlant Biotechnologies announced that its subsidiary, LightSolver Ltd., secured a paid collaboration with the Israel Ministry of Defense to develop photonic computing technology.
Why it matters — The collaboration is an announcement involving a CollPlant subsidiary and its technology-development work.
Of the 1 analysts covering CollPlant Biotechnologies Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CollPlant Biotechnologies Ltd. 31 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, CollPlant Biotechnologies Ltd. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No analyst covering CollPlant Biotechnologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPHI are extrapolating price history, which says nothing about the business.
CollPlant Biotechnologies Ltd. returned -75.4% over the 12 months to 12 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on developing medical products based on its recombinant human collagen technology.
The most recent item we track (GlobeNewsWire, 12 Nov 2026): "CollPlant to Begin Trading on Nasdaq Under New Ticker Symbol “OPHI”". CollPlant will begin trading on Nasdaq under the ticker symbol OPHI. The company described the change as a step in its strategy to expand and focus operations around LightSolver’s all-optical Laser Processing Unit (LPU).
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on developing medical products based on its recombinant human collagen technology. The company’s current portfolio centers on 3D bioprinting for tissues and organs, tissue repair, advanced wound care, and medical aesthetics. Its offerings include bioinks and collagen-based materials designed for regenerative applications, along with products used in soft tissue repair and wound management. CollPlant Biotechnologies also works with partners and collaborators in the broader medical device and biotech ecosystem, supporting applications in orthobiologics, surgical repair, and aesthetic medicine. Headquartered in Rehovot, Israel, CollPlant Biotechnologies Ltd. plays a niche role in the market by combining plant-based biotechnology with collagen innovation for healthcare uses.
CEO Mr. Yehiel Tal · 39 employees · Israel · https://collplant.com
